Disruption of the podocyte–endothelial–VEGF axis results in loss of endothelial fenestrations, endotheliosis, podocytes loss, and subsequent proteinuria.5,8 Pathological findings often include kidney-limited thrombotic microangiopathy (TMA) (Figure 5) in patients treated with VEGF inhibitors and minimal change disease or focal segmental glomerulosclerosis with mTKIs.5,6. This evidence concerns the gene VEGFA and lipoid nephrosis.